UK scientists are developing a vaccine for the Bundibugyo strain of Ebola, a rare species that kills around a third of those infected and currently has no proven vaccine. The Oxford Vaccine Group is leading the development using the same technology behind the AstraZeneca Covid-19 vaccine, with trials potentially ready within months.
The Ebola outbreak in the Democratic Republic of Congo (DRC) is "spreading rapidly," according to the director-general of the World Health Organisation (WHO). The outbreak has prompted international health attention as scientists work to develop countermeasures.
The Bundibugyo strain of Ebola represents one of several species of the virus. Unlike other Ebola strains that have existing vaccine options, Bundibugyo has no approved vaccine, leaving populations vulnerable to infection. The strain kills around a third of those infected.
The Oxford Vaccine Group's approach leverages established vaccine technology. The same platform used to create the AstraZeneca Covid-19 vaccine is being adapted to target the Bundibugyo strain. This technology uses a modified adenovirus to deliver genetic instructions to cells, prompting an immune response without causing disease.
Clinical trials for the new vaccine could begin within months, according to reports. The timeline reflects both the urgency of the current outbreak and the advantages of building upon existing vaccine technology rather than starting development from scratch.
The WHO has been monitoring the situation in the DRC, where Ebola outbreaks have occurred repeatedly over the years. The organization's director-general has characterized the current spread as rapid, underscoring the need for effective interventions.
The development of a Bundibugyo-specific vaccine would address a gap in global health preparedness. Previous Ebola outbreaks prompted accelerated vaccine development for other strains, but Bundibugyo has received less attention from pharmaceutical research.
Health officials continue to track the outbreak's progression while vaccine development proceeds. The combination of established technology and experienced research teams at Oxford provides a pathway for potential vaccine availability in the near term.
Read the original coverage
💬 Comments
📜 Comment Policy